First Place Ranking
The Emory Nell Hodgson Woodruff School of Nursing's Bachelor of Science (BSN) program is No. 1 in the nation
, according to rankings released by US News & World Report. With this ranking, the school is No. 1 in BSN and master’s degree programs among US nursing schools. The School of Nursing has been in the top five in the US News' BSN rankings since they began in 2021. “Having two No. 1 programs is a remarkable achievement,” says Dean Linda McCauley. “It shines a light on our commitment to visionary nurse leadership and our efforts to enhance the profession and health care. I am delighted for our entire school community.” –Best Colleges 2024, US News & World Report.
AI Poised to Transform Neurological Care
“Artificial intelligence will improve care by assisting—not replacing—clinicians and researchers by providing a new perspective that integrates multiple layers and types of data into personalized clinical or preclinical predictions.”–Cassie Mitchell, assistant professor, Coulter Department of Biomedical Engineering at Georgia Tech and Emory, at the American Neurological Association AI Symposium.
Deep-Breathing Benefits
Brain scans show slower breathing reduces anxiety and fear, while increasing the ability to reason, so the thinking mind restrains the emotional part of the mind, helping a person evaluate the situation better.
Deeper, slower breathing can also let your body know to come out of fight-or-flight mode, says Anne Bartolucci, clinical psychologist, adjunct assistant professor at Emory School of Medicine and author of Better Sleep for the Overachiever.
“It’s a nice, quick way to calm down, and it’s also a way to signal to yourself that you’re taking care of yourself,” Bartolucci says.–“Six Breathing Exercises to Ease Stress and Anxiety,” Today.com
Twice Yearly Injectable Reduces HIV Risk
In the United States the stubbornly high rate of HIV diagnoses—especially in the US South, and particularly among gay and bisexual men of color and transgender people—demands novel approaches to help people prevent HIV acquisition,” says Colleen Kelley, professor of medicine at Emory and a principal investigator in the Purpose 2 Phase 3 trial. “Because adherence to oral products can be challenging for some people, twice-yearly injectable lenacapavir for PrEP has the potential to be one of the most impactful interventions we could have to drive down new infections and bring us closer to ending the HIV epidemic in the United States.”–“Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96%,” ADVOCATE
Email the Editor 
